1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Jan 2021
Admin
News Article

Genkyotex Announces Positive Phase 1 Data Of High-Dose Setanaxib In Primary Biliary Cholangitis Patients

Genkyotex Sa, A Subsidiary Of Calliditas Therapeutics Ab (Publ), Announced Positive Phase 1 Data Demonstrating A Favorable Safety And Pharmacokinetic Profile Of High-Dose Setanaxib, Genkyotex'S Lead Asset.The Phase 1 Study Demonstrated That Setanaxib Is Well Tolerated At The Doses Tested, With No Safety Signal Or Dose-Limiting Toxicity Being Identified. The Results Provide An Opportunity For The Company To Pursue A Pivotal Phase 2/3 Clinical Trial In Patients With Primary Biliary Cholangitis (Pbc), Based On Interactions With The Us Fda.The Study Assessed The Safety And Pharmacokinetics Of Oral Setanaxib At Selected Doses In 46 Healthy Adult Male And Female Subjects. The Trial Consisted Of A Single Ascending Dose (Sad) Part And A Multiple Ascending Dose (Mad) Part With Dosing Up To 1600Mg/Day.Previously, Doses Of Up To 800 Mg/Day Were Evaluated In A 24-Week Phase 2 Trial In Pbc Patients. In That Trial, Setanaxib Dosed At 800 Mg/Day Achieved Reductions In Markers Of Cholestasis, Including Alkaline Phosphatase, And In Multiple Non-Invasive Markers Of Liver Fibrogenesis, Including Liver Stiffness And Pro-C3 And C3M. Significant Improvement In Fatigue Was Also Achieved. All Doses Tested In That Trial Were Well-Tolerated, With No Safety Signal Compared To Placebo."This Result Provides A Foundation For A Clinical Development Program Using Higher Doses Of Setanaxib Across A Variety Of Orphan Indications. This Includes The Potential To Launch A Pivotal Phase 2/3 Trial With A Clearly Differentiated Drug Candidate In Pbc But Will Also Allow Us To Further Explore A Select Number Of Kidney Related Orphan Diseases In Which Inflammation And Fibrosis Play A Part.", Said Ceo RenÉE Aguiar-Lucander.Calliditas Acquired 62.7% Of The Share Capital And Voting Rights Of Genkyotex, In November 2020, Before Submitting A Simplified Public Mandatory Offer To The Shareholders Of Genkyotex On 26 November 2020. Calliditas Controls 86.2% Of The Share Capital And Total Number Of Votes Of Genkyotex

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!